Guardant Health, Inc.

GH

US40131M1099

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:42:20 2024-07-16 am EDT			5-day change	1st Jan Change
32.2 ^USD	+2.11%		+16.75%	+19.33%

Jul. 12	GoodRx Holdings, Inc. Announces the Election of Ian T. Clark to its Board of Directors	CI
Jun. 28	Top Premarket Gainers	MT

Guardant Health Inc. Appoints Ian Clark as its Board of Directors

January 06, 2017 at 09:15 am EST

Guardant Health Inc. announced that Ian Clark has joined its board of directors. Clark served as the CEO of Genentech and head of North American Commercial Operations.

Latest news about Guardant Health, Inc.

GoodRx Holdings, Inc. Announces the Election of Ian T. Clark to its Board of Directors	Jul. 11	CI
Top Premarket Gainers	Jun. 28	MT
Guggenheim Upgrades Guardant Health to Buy From Neutral, Price Target at $36	Jun. 28	MT
Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors and Chairperson of Audit Committee	Jun. 13	CI
Transcript : Guardant Health, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:00 PM	Jun. 11
Canaccord Genuity Adjusts Price Target on Guardant Health to $38 From $30, Maintains Buy Rating	Jun. 04	MT
Guardant Health Introduces New Guardant360 Tissuenext Test with Nearly 500 Biomarkers to Identify More Treatment Options for Patients with Advanced Cancer	Jun. 04	CI
Jefferies Initiates Guardant Health at Buy Rating With $32 Price Target	Jun. 03	MT
Sector Update: Health Care Stocks Softer in Friday Afternoon Trading	May. 24	MT
Guardant Health's Shares Rise as Colorectal Cancer Detection Test Gets FDA Panel Recommendation	May. 24	MT
Sector Update: Health Care Stocks Advance Pre-Bell Friday	May. 24	MT
Sector Update: Health Care	May. 24	MT
Wall Street Rebounds From Thursday's Slide, Driving Narrow Gains for US Equity Futures Pre-Bell	May. 24	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday as Investors Hope for September Interest Rate Cuts	May. 24	MT
Top Premarket Gainers	May. 24	MT
Guardant Health Says Colorectal Cancer Detection Test Receives FDA Panel Recommendation	May. 24	MT
Guardant Health, Inc. Announces FDA Advisory Committee Panel Strongly Recommends Approval of Shield? Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option	May. 23	CI
Guardant Health Gets FDA Panel Recommendation for Cancer-Screening Blood Test	May. 23	DJ
U.S. FDA advisers back approval for Guardant's cancer test	May. 23	RE
Guardant Health Shares Halted; FDA Panel to Review Premarket Application of Colorectal Cancer Screening Test	May. 23	MT
Guardant Health Gets EU Certification for Blood-Based Test for Comprehensive Genomic Profiling of Solid Cancers	May. 21	MT
Guardant Health, Inc. Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications	May. 21	CI
Transcript : Guardant Health, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM	May. 15
Guardant Health Shares Rise After Q1 Adjusted Loss Shrinks, Revenue Rises; 2024 Revenue Guidance Raised	May. 10	MT
Guardant Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Guardant Health, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

31.54 USD

Average target price

37.7 USD

Spread / Average Target

+19.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
GUARDANT HEALTH, INC.	+19.33%	3.86B
EXACT SCIENCES CORPORATION	-35.87%	8.68B
IOVANCE BIOTHERAPEUTICS, INC.	+13.28%	2.43B
BGI GENOMICS CO., LTD.	-27.10%	1.84B
VERACYTE, INC.	-15.30%	1.73B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+34.81%	1.16B
CAREDX, INC	+43.56%	842M
SEEGENE, INC.	-8.30%	702M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-14.39%	594M
CURIOX BIOSYSTEMS CO., LTD	-18.19%	239M

Bio Diagnostics & Testing